Skip to main content
Inify Laboratories AB logo

Inify Laboratories AB — Investor Relations & Filings

Ticker · INIFY ISIN · SE0017486103 LEI · 549300306YYJ3BX3VB98 ST Human health and social work activities
Filings indexed 339 across all filing types
Latest filing 2025-10-29 Interim / Quarterly Rep…
Country SE Sweden
Listing ST INIFY

About Inify Laboratories AB

https://www.inify.com/

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. The company utilizes a fully digital, standardized, and AI-supported workflow for histopathology analysis. This integrated service model is designed to optimize the entire diagnostic process, from sample receipt to final report, ensuring high quality and significantly reduced turnaround times for clinical partners. Initially focused on prostate cancer, the company has expanded its diagnostic capabilities to include other areas such as gastroenterology. By streamlining the clinical pathway, Inify Laboratories enables healthcare providers to receive faster results, which facilitates earlier patient follow-up and treatment planning.

Recent filings

Filing Released Lang Actions
Inify Laboratories: De första diagnoserna inom mag-tarmområdet har levererats och den kliniska verksamheten i Storbritannien är på god väg mot öppning i början av 2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport tredje kvartalet 2025' (Interim Report for the third quarter of 2025) for Inify Laboratories. It contains detailed financial statements, key performance indicators (KPIs), management commentary on business development, and operational updates for the specified period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q3 2025
2025-10-29 Swedish
Inify Laboratories - mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is a 'mandatory notification of trade' regarding a board member (primary insider) acquiring shares in the company. This explicitly falls under the category of Director's Dealing, which covers personal share transactions by company directors and executives.
2025-08-29 English
Inify Laboratories: Stabil tillväxt i Sverige och första patientdiagnostiken levererad i Storbritannien - Attachment: Inify_Laboratories_Delarsrapport_Q2_2025.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Inify Laboratories Delårsrapport andra kvartalet 2025' (Interim Report Q2 2025). It contains comprehensive financial statements, including income statements, balance sheet data, cash flow analysis, and management commentary on business performance, market expansion, and operational highlights. It is a full interim report, not an announcement or a summary, and contains substantive financial data. Q2 2025
2025-08-27 Swedish
Inify Laboratories: Solid growth in Sweden and first patient diagnostics delivered in the UK - Attachment: Inify_Laboratories_Financial_Report_Q2_2025.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the second quarter 2025' and contains comprehensive financial statements, key figures (Q2 2025 vs Q2 2024), management commentary, and operational updates for the company Inify Laboratories. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q2 2025
2025-08-27 English
Inify Laboratories: Sterk vekst i Sverige og første pasientdiagnostikk levert i Storbritannia - Attachment: Inify_Laboratories_Financial_Report_Q2_2025.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the second quarter 2025' and contains comprehensive financial statements, key figures (Q2 2025 vs Q2 2024), management commentary, and operational updates for the company Inify Laboratories. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q2 2025
2025-08-27 English
Inify Laboratories: Stabil tillväxt i Sverige och första patientdiagnostiken levererad i Storbritannien
Earnings Release Classification · 100% confidence The document is a press release from Inify Laboratories detailing their financial performance (revenue growth, cash position) and operational milestones (expansion in Sweden and the UK) for the second quarter of 2025. It provides key highlights of the financial results rather than the full comprehensive financial report. According to the filing definitions, an initial announcement of quarterly financial results is classified as an Earnings Release (ER). Q2 2025
2025-08-27 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.